Paion AG (PAIOF) Financial

PAION AG operates as a pharmaceutical company, which engages in the development of drugs to be used in out-patient and hospital-based sedation, anesthesia, and critical care services. The company is headquartered in Aachen, Nordrhein-Westfalen and currently employs 64 full-time employees. The company went IPO on 2005-02-11. The firm's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The firm operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.